title: Clinical features and treatment strategies for older prostate cancer patients with bone metastasis.
abstract: To identify the clinical features and independent predictors of survival in older patients with bone metastasis from prostate cancer (PCa). We retrospectively analysed 205 older patients with bone metastases from PCa between 1997 and 2012. The Kaplan-Meier method was used with the log-rank test for survival rate calculations and to evaluate each variable. Multivariate analysis was performed with the Cox regression model. The chi-squared test was used to compare survival rates between older and younger (n=197) patients. All patients were followed up. The 1-, 2-, 3- and 5-year survival rates were 95.5%, 77.5%, 68.5% and 33.7%, respectively. Gleason score, radiotherapy of the primary tumour, the number of bone metastases, the alkaline phosphatase alkaline phosphatase (ALP) level, organ metastasis and regional lymph node metastasis were associated with the survival rates. Multivariate Cox regression analysis showed that Gleason score at diagnosis of the primary tumour was a significant predictor of overall survival following the diagnosis of bone metastases. In addition, the overall survival rates of older patients were higher compared with younger patients, but older patients who underwent radiotherapy had higher mortality. These data may serve as a guide for creating clinical prediction models in further studies.
authors.affiliation: Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
authors.forename: Cheng
authors.initials: C
authors.lastname: Yang
authors.forename: Gui-Sheng
authors.initials: GS
authors.lastname: Qi
authors.forename: Rui-Ming
authors.initials: RM
authors.lastname: Rong
authors.forename: Jian
authors.initials: J
authors.lastname: He
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000473:pathology* / Q000556:secondary* / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D011379:Prognosis
references.citation: CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
references.pmid: 21685461
references.citation: Adv Exp Med Biol. 1992;324:29-38
references.pmid: 1492623
references.citation: Urol Oncol. 2011 Mar-Apr;29(2):162-5
references.pmid: 19450995
references.citation: Cancer. 2002 Sep 1;95(5):1028-36
references.pmid: 12209687
references.citation: Br J Urol. 1984 Aug;56(4):385-90
references.pmid: 6534426
references.citation: J Urol. 2012 Oct;188(4):1164-9
references.pmid: 22921015
references.citation: J Urol. 2002 Oct;168(4 Pt 1):1423-6
references.pmid: 12352409
references.citation: Br J Cancer. 2013 Jan 15;108(1):9-13
references.pmid: 23321508
references.citation: J Cancer Res Clin Oncol. 2013 Jul;139(7):1141-7
references.pmid: 23552872
references.citation: Eur Urol. 2003 Mar;43(3):226-32
references.pmid: 12600424
references.citation: Clin Interv Aging. 2012;7:363-72
references.pmid: 23049248
references.citation: J Urol. 1997 Jul;158(1):164-70
references.pmid: 9186346
references.citation: Clin Prostate Cancer. 2003 Jun;2(1):41-5
references.pmid: 15046683
references.citation: Urology. 2008 Dec;72(6):1287-92
references.pmid: 18372020
references.citation: Carcinogenesis. 2008 Aug;29(8):1509-18
references.pmid: 18453541
references.citation: J Urol. 2003 Jan;169(1):164-9
references.pmid: 12478127
references.citation: Asian J Androl. 2012 May;14(3):505-8
references.pmid: 22504872
references.citation: Prescrire Int. 2013 Mar;22(136):74-8
references.pmid: 23593699
references.citation: Practitioner. 2013 Apr;257(1760):15-8, 2
references.pmid: 23724747